European Commission expands VENCLYXTO label to include acalabrutinib- and ibrutinib-based fixed-duration combinations for previously untreated CLL, supported by AMPLIFY, GLOW, and CAPTIVATE trial data.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
The European Commission has authorized an expanded label for AbbVie’s VENCLYXTO® (venetoclax), permitting its use in combination with acalabrutinib, with or without obinutuzumab, and in combination with ibrutinib for adults with previously untreated chronic lymphocytic leukemia (CLL). The approval extends across all European Union member states as well as Iceland, Norway, and Liechtenstein, expanding access to fixed-duration, chemotherapy-free oral regimens for first-line CLL.
The label expansion is supported by evidence from three clinical studies: the Phase 3 AMPLIFY trial evaluating venetoclax plus acalabrutinib, the Phase 3 GLOW trial evaluating venetoclax plus ibrutinib, and the Phase 2 CAPTIVATE study, which provided long-term follow-up data for the venetoclax-ibrutinib regimen.
Together, these studies demonstrated durable disease control, prolonged progression-free survival, and the potential for extended treatment-free intervals in previously untreated patients with CLL.
Clinical Evidence
AMPLIFY Trial
In the Phase 3 AMPLIFY study (NCT03836261), venetoclax plus acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmunotherapy in previously untreated patients without del(17p) or TP53 mutations. Median progression-free survival (PFS) was not reached in the venetoclax arms versus 47.6 months for chemoimmunotherapy. Safety findings were consistent with the known profiles of the individual agents, and no new safety signals were reported.
GLOW Trial
The Phase 3 GLOW trial (NCT03462719) showed that fixed-duration venetoclax plus ibrutinib reduced the risk of disease progression or death by 73% and the risk of death by 54% versus chlorambucil plus obinutuzumab after 64 months of follow-up. Median PFS reached 65 months compared with 23 months in the comparator arm. The regimen demonstrated a safety profile consistent with the known effects of the individual therapies and showed no cases of tumor lysis syndrome.
CAPTIVATE Study
Long-term data from the Phase 2 CAPTIVATE trial (NCT02910583) further supported the regimen, with 5.5-year PFS and overall survival rates of 66% and 97%, respectively. Notably, 73% of patients remained treatment-free 5.5 years after completing 15 months of therapy, highlighting the durability of response achievable with a fixed-duration approach.
Mechanism of Action
Venetoclax is a selective inhibitor of the B-cell lymphoma 2 (BCL-2) protein, which enables malignant lymphocytes to evade apoptosis. By blocking BCL-2, venetoclax restores programmed cell death in cancer cells. CLL is the most common adult leukemia and remains incurable despite major advances in targeted therapy, making durable, time-limited treatment approaches an important goal.
Clinical Significance
Svetlana Kobina, MD, PhD, vice president of global medical affairs, oncology at AbbVie, emphasized that the expanded label introduces new fixed‑duration, chemotherapy‑free oral regimens for patients with previously untreated CLL, offering physicians and patients greater flexibility in care.
The European Commission’s decision broadens access to time‑limited targeted approaches across Europe, reinforcing the growing role of fixed‑duration regimens in frontline CLL treatment. By providing additional oral options that can sustain durable disease control while enabling treatment‑free intervals, the approval marks a significant step toward reducing long‑term treatment burden in clinical practice.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.